Drug intelligence / Profile preview

bisoprolol + perindopril + amlodipine

Development stage
Phase 3
Lead developer
Servier
Modality
Small Molecules
Administration
Oral
01

Overview

bisoprolol + perindopril + amlodipine is a fixed-dose triple combination (FDC) therapy developed by Servier for the treatment of hypertension, particularly in patients whose blood pressure is not adequately controlled by dual therapy. The combination integrates three antihypertensive agents with complementary mechanisms: **perindopril**, an angiotensin-converting enzyme (ACE) inhibitor that reduces systemic vascular resistance; **amlodipine**, a dihydropyridine calcium channel blocker (CCB) that induces peripheral vasodilation; and **bisoprolol**, a selective beta-1 adrenergic receptor blocker that reduces heart rate and cardiac output. By targeting the renin-angiotensin-aldosterone system, calcium-mediated vasoconstriction, and sympathetic activity simultaneously, the therapy provides robust blood pressure control. It is formulated as a single-pill (capsule) to reduce pill burden and improve patient adherence.

Brand names
Tri-Cosyrel
Other names
bisoprolol fumarate + perindopril arginine + amlodipine besylateperindopril arginine/amlodipine/bisoprolol fumarate
02

Targets

ACE (Angiotensin Converting Enzyme)ADRB1 (β1)LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on bisoprolol + perindopril + amlodipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bisoprolol + perindopril + amlodipine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call